Source link : https://newshealth.biz/health-news/postoperative-crizotinib-fails-in-early-lung-cancer/
(MedPage Today) — Adjuvant crizotinib (Xalkori) failed to improve disease-free survival (DFS) in patients with surgically resected early-stage ALK-positive non-small cell lung cancer (NSCLC), the phase III ECOG-ACRIN E4512 trial showed. Among… Source link : https://www.medpagetoday.com/meetingcoverage/iaslc/117362 Author : Publish date : 2025-09-08 18:52:00 Copyright for syndicated content belongs to the linked Source.
The post Postoperative Crizotinib Fails in Early Lung Cancer first appeared on News Health.
—-
Author : News Health
Publish date : 2025-09-08 18:52:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8